Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Coghill

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
European Child & Adolescent Psychiatry|April 22, 2017
Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorderDavid R Coghill, Tobias Banaschewski, César Soutullo, et al.
Journal of Psychopharmacology (Oxford, England)|February 12, 2020
Post hoc analyses of response rates to pharmacological treatments in children and adolescents with attention-deficit/hyperactivity disorderDavid R Coghill, Jeffrey H Newcorn, Jie Chen, et al.
Biological Psychiatry|November 16, 2013
Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysisDavid R Coghill, Sarah Seth, Sara Pedroso, et al.
Journal of Attention Disorders|August 25, 2017
Correlations Between Clinical Trial Outcomes Based on Symptoms, Functional Impairments, and Quality of Life in Children and Adolescents With ADHDDavid R Coghill, Alain Joseph, Vanja Sikirica, et al.
European Child & Adolescent Psychiatry|July 22, 2020
Functional impairment outcomes in clinical trials of different ADHD medications: post hoc responder analyses and baseline subgroup analysesDavid R Coghill, Tamara Werner-Kiechle, Sepehr Farahbakhshian, et al.
Neuropsychiatric Disease and Treatment|November 8, 2014
Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trialDavid R Coghill, Tobias Banaschewski, Michel Lecendreux, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|October 27, 2009
The MTA at 8Tobias Banaschewski, Jan Buitelaar, David R Coghill, et al.
CNS Drugs|July 2, 2017
Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in EuropeDavid R Coghill, Tobias Banaschewski, Peter Nagy, et al.
European Child & Adolescent Psychiatry|May 23, 2015
Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidatePeter Nagy, Alexander Häge, David R Coghill, et al.
CNS Drugs|August 21, 2014
Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorderTobias Banaschewski, Mats Johnson, Michel Lecendreux, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
European Child & Adolescent Psychiatry|April 22, 2017
Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorderDavid R Coghill, Tobias Banaschewski, César Soutullo, et al.
Journal of Psychopharmacology (Oxford, England)|February 12, 2020
Post hoc analyses of response rates to pharmacological treatments in children and adolescents with attention-deficit/hyperactivity disorderDavid R Coghill, Jeffrey H Newcorn, Jie Chen, et al.
Biological Psychiatry|November 16, 2013
Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysisDavid R Coghill, Sarah Seth, Sara Pedroso, et al.
Journal of Attention Disorders|August 25, 2017
Correlations Between Clinical Trial Outcomes Based on Symptoms, Functional Impairments, and Quality of Life in Children and Adolescents With ADHDDavid R Coghill, Alain Joseph, Vanja Sikirica, et al.
European Child & Adolescent Psychiatry|July 22, 2020
Functional impairment outcomes in clinical trials of different ADHD medications: post hoc responder analyses and baseline subgroup analysesDavid R Coghill, Tamara Werner-Kiechle, Sepehr Farahbakhshian, et al.
Neuropsychiatric Disease and Treatment|November 8, 2014
Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trialDavid R Coghill, Tobias Banaschewski, Michel Lecendreux, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|October 27, 2009
The MTA at 8Tobias Banaschewski, Jan Buitelaar, David R Coghill, et al.
CNS Drugs|July 2, 2017
Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in EuropeDavid R Coghill, Tobias Banaschewski, Peter Nagy, et al.
European Child & Adolescent Psychiatry|May 23, 2015
Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidatePeter Nagy, Alexander Häge, David R Coghill, et al.
CNS Drugs|August 21, 2014
Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorderTobias Banaschewski, Mats Johnson, Michel Lecendreux, et al.
Pageof 4